Imipenem monohydrate, 98%
Element SearchElement SearchStructure SearchStructure Search
Imipenem monohydrate, 98%
Imipenem monohydrate, 98%
Imipenem monohydrate, 98%

Imipenem monohydrate, 98%

Imipenem monohydrate,Tienam, Primaxin, CAS # 74431-23-5 is a broad-spectrum carbapenem antibiotic that interferes with the activity of penicillin binding proteins along the inner cell wall.
Have Questions?
Change viewbuttonViewtableView
Quantity:
250 mg
1 g
Catalog number FSA455322500
View Price:Sign in to see your account pricing. Need an account? Register with us today.
Quantity:
250 mg
Request bulk or custom format
Specifications
Chemical Name or MaterialImipenem monohydrate
TypeImipenem Monohydrate
CAS74431-23-5
Melting Point193.0°C to 198.0°C
Infrared SpectrumAuthentic
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General description
• Imipenem monohydrate is a beta-lactam derived from the compound thienamycin, produced by Streptomyces cattleya
• Disrupts cell wall integrity, preventing cell division and promoting lysis by interfering with the activity of penicillin binding proteins
• Imipenem is a third-generation cephalosporin that can kill both gram-negative and gram-positive bacteria

Applications
• Suitable for the study of antibiotic resistance
• High-quality, laboratory grade for use in vitro and in vivo experiments

RUO – Research Use Only

General References:

  1. Pericàs, J.M.; Moreno, A.; Almela, M.; García-de-la-Mària, C.; Marco, F.; Muñoz, P.; Peña, C. de Alarcón, A.; Del Río, A.; Eworo, A.; Cruceta, A.; Paré, J.C.; Mestres, C.A.; Miró, J.M. FOSIMI Investigators. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. Clin Microbiol Infect. 2018, 24(6), 673-676.
  2. Chavan, V.V.; Dalal, A.; Nagaraja, S.; Thekkur, P.; Mansoor, H.; Meneguim, A.; Paryani, R.; Singh, P.; Kalon, S.; Das, M.; Ferlazzo, G.; Isaakidis, P. Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges. PLoS One. 2020, 16;15(6), e0234651.